ISSN (print) 1997-6933     ISSN (online) 2500-2139
Vol. 17 No. 1 (2024), LYMPHOID TUMORS
Vol. 17 No. 1 (2024)
LYMPHOID TUMORS

Treatment of Patients with Local Stages of Newly Diagnosed Classical Hodgkin Lymphoma: A Literature Review, Current Approaches, and Our Own Experience

Published 17.05.2024
Evgeniya Viktorovna Paramonova
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
Yu.I. Klyuchagina
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
M.Yu. Kichigina
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
D.N. Tupitsyna
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
V.O. Shpirko
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
A.V. Arakelyan
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522; IM Sechenov First Moscow State Medical University, 2 korp. 4 Bolshaya Pirogovskaya ul., Moscow, Russian Federation, 119435
A.A. Semenova
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
E.A. Demina
NI Pirogov National Medical and Surgical Center, 70 Nizhnyaya Pervomaiskaya ul., Moscow, Russian Federation, 105203
O.P. Trofimova
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
A.S. Subbotin
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
M.A. Senchenko
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
G.S. Tumyan
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
2024-1
PDF_2024-17-1_27-36 (Russian)

Keywords

classical Hodgkin lymphoma
prognostic groups
local stages
combined PET/CT
treatment

How to Cite

Paramonova E.V., Klyuchagina Y.I., Kichigina M.Y., Tupitsyna D.N., Shpirko V.O., Arakelyan A.V., Semenova A.A., Demina E.A., Trofimova O.P., Subbotin A.S., Senchenko M.A., Tumyan G.S. Treatment of Patients with Local Stages of Newly Diagnosed Classical Hodgkin Lymphoma: A Literature Review, Current Approaches, and Our Own Experience. Clinical Oncohematology. 2024;(1):27–36. doi:10.21320/2500-2139-2024-17-1-27-36.
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA ГОСТ

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Keywords

Abstract

Aim. To determine an optimal amount of program therapy for patients with local (I/II) stages of newly diagnosed classical Hodgkin lymphoma (cHL) who are stratified into prognostic groups by different risk factors (RF).

Materials & Methods. The present study is based on the clinical data from 125 patients with local (I/II) stages of newly diagnosed cHL. All of them were treated at the NN Blokhin National Medical Cancer Research Center from 2000 to 2022. The patients were aged 18–67 years (median 29 years), most of them were women (n = 90; 72 %). The patients were stratified into 3 prognostic groups with respect to the following RFs: В-symptoms, ESR level, bulky mediastinum, lesion number, and stage E. Group 1 regarded as prognostically favorable (stages I/IIA without RFs) included 22 (18 %) patients; group 2 with intermediate prognosis (stages I/IIA–В, ≥ 3 lesions and/or ESR ≥ 30 mm/h with B-symptoms or ESR ≥ 50 mm/h without them) consisted of 45 (36 %) patients; group 3 regarded as prognostically unfavorable (stages I/IIА, bulky mediastinum and/or extranodal lesions, i.e. stage Е) included 58 (46 %) patients. In group 1, there were no patients with B-symptoms. In group 3, patients with intoxication symptoms were excluded from the analysis. Chemotherapy programs in prognostic groups (risk groups) differed: 2–4 ABVD cycles in group 1 and 6 EACOPP-14 cycles in group 3. Both regimens were used in group 2. This was the category of patients with intermediate prognosis which required modifications in the drug therapy program due to the interim PET2 results and continued in the form of de-escalated treatment: 2 ЕАСОРР-14 cycles → PET2-negative status → 2 AVD cycles (n = 20). This model proved to be most effective by the present study and did not exclude the applicability of the programs either with 4 cycles of ЕАСОРР-14 alone (n = 12) or 4–6 cycles of ABVD alone (n = 13) in the group of intermediate prognosis. After completing the drug therapy phase, radiotherapy was performed in 113 (91 %) patients.

Results. The median follow-up was 46 months. Taken as a whole, the treatment showed high efficacy: the 5-year progression-free survival appeared to be 93 %, and the 5-year overall survival was 99 %.

Conclusion. The stratification of patients into 3 prognostic groups (favorable, intermediate, and unfavorable) provides the basis for determining a drug chemotherapy program which would be optimal in its amount, efficacy, and toxicity profile for patients with local stages of newly diagnosed cHL. Further study of escalation and de-escalation strategies in the program chemotherapy for patients with stages I/IIA of newly diagnosed cHL having or not having a bulky tumor mass in mediastinum, based on PET2 results, can help to improve, first of all, the quality of life of patients as well as short- and long-term chemotherapy outcomes in general. In this context, chemotherapy escalation is possible in the cases of PET2-positive status, whereas its de-escalation would be considered in the cases of PET2-negative status.

PDF_2024-17-1_27-36 (Russian)

References

  1. Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med. 2007;357(19):1916–27. doi: 10.1056/NEJMoa064601.
  2. Diehl V, Stein H, Hummel M, et al. Hodgkin’s lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc Hematol Educ Program. 2003;225–47. doi: 10.1182/asheducation-2003.1.225.
  3. Klimm B, Goergen H, Fuchs M, et al. Impact of risk factors on outcomes in early-stage Hodgkin’s lymphoma: an analysis of international staging definitions. Ann Oncol. 2013;24(12):3070–6. doi: 10.1093/annonc/mdt413.
  4. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. М.: Буки Веди, 2018. 324 с. [Poddubnaya IV, Savchenko VG, eds. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniyu limfoproliferativnykh zabolevanii. (Russian clinical guidelines on diagnosis and treatment of lymphoproliferative disorders.) Moscow: Buki Vedi Publ.; 2018. 324 р. (In Russ)]
  5. Von Tresckow B, Plutschow A, Fuchs M, et al. Dose-Intensification in Early Unfavorable Hodgkin’s Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial. J Clin Oncol. 2012;30(9):907–13. doi: 10.1200/JCO.2011.38.5807.
  6. Behringer K, Thielen I, Mueller H, et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Ann Oncol. 2012;23(7):1818–25. doi: 10.1093/annonc/mdr575.
  7. Swerdlow AJ, Higgins CD, Smith P, et al. Second cancer risk after chemotherapy for Hodgkin’s lymphoma: a collaborative British cohort study. J Clin Oncol. 2011;29(31):4096–104. doi: 10.1200/JCO.2011.34.8268.
  8. Lang N, Crump M. PET-adapted approaches to primary therapy for advanced Hodgkin lymphoma. Ther Adv Hematol. 2020;11:2040620720914490. doi: 10.1177/2040620720914490.
  9. Borchmann P, Plutschow A, Kobe С, et al. PET-Guided Omission of Radiotherapy in Early-Stage Unfavourable Hodgkin Lymphoma (GHSG HD17): A Multicentre, Open-Label, Randomised, Phase 3 Trial. Lancet Oncol. 2021;22(2):223–34. doi: 10.1016/S1470-2045(20)30601-X.
  10. Andre MP, Girinsky T, Federico M, et al. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol. 2017;35(16):1786–94. doi: 10.1200/JCO.2016.68.6394.
  11. Follows AM, Santarsieri A. Minimising the Toxicities of First Line Hodgkin Lymphoma Treatment in the Modern Era. Cancers (Basel). 2022;14(21):5390. doi: 10.3390/cancers14215390.
  12. De Vries S, Schaapveld M, Janus CPM, et al. Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients. J Natl Cancer Inst. 2021;113(6):760–9. doi: 10.1093/jnci/djaa194.
  13. Engert A, Plutschow A, Eich HT, et al. Reduced Treatment Intensity in Patients with Early-Stage Hodgkin’s Lymphoma. N Engl J Med. 2010;363(7):640–52. doi: 10.1056/NEJMoa1000067.
  14. Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: Results from the HD2000 gruppo Italiano Per lo studio dei linfomi trial. J Clin Oncol. 2009;27(5):805–11. doi: 10.1200/JCO.2008.17.0910.
  15. Duggan DB, Petroni GR, Johnson JL, et al. Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkin’s Disease: Report of an Intergroup Trial. J Clin Oncol. 2003;21(4):607–14. doi: 10.1200/JCO.2003.12.086.
  16. Behringer K, Goergen H, Hitz F, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): An open-label, randomised, non-inferiority trial. Lancet. 2015;385(9976):1418–27. doi: 10.1016/S0140-6736(14)61469-0.
  17. Boll B, Goergen H, Behringer K, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016;127(18):2189–92. doi: 10.1182/blood-2015-11-681064.
  18. Follows GA, Barrington SF, Bhuller KS, et al. Guideline for the first-line management of Classical Hodgkin Lymphoma—A British Society for Haematology guideline. Br J Haematol. 2022;197(5):558–72. doi: 10.1111/bjh.18083.
  19. Демина Е.А., Леонтьева А.А., Тумян Г.С. и др. Оптимизация терапии первой линии у пациентов с распространенными стадиями лимфомы Ходжкина: эффективность и токсичность интенсивной схемы ЕАСОРР-14 (опыт ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России). Клиническая онкогематология. 2017;10(4):443–52. doi: 10.21320/2500-2139-2017-10-4-443-452. [Demina EA, Leont’eva AA, Tumyan GS, et al. First-Line Therapy for Patients with Advanced Hodgkin’s Lymphoma: Efficacy and Toxicity of Intensive ЕАСОРР-14 Program (NN Blokhin National Medical Cancer Research Center Data). Clinical oncohematology. 2017;10(4):443–52. doi: 10.21320/2500-2139-2017-10-4-443-452. (In Russ)]
  20. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin’s Lymphoma. N Engl J Med. 2012;366(5):399–408. doi: 10.1056/NEJMoa1111961.
  21. Radford J, Barrington S, Counsell N, et al. Involved field radiotherapy vs no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a ‘negative’ PET scan after 3 cycles ABVD: results of the UK NCRI RAPID trial. Blood. 2012;120(21):547.
  22. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107(1):52–9. doi: 10.1182/blood-2005-06-2252.
  23. Chohan K, Young J, Lester S. End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET. Haematologica. 2023;108(6):1697–701. doi: 10.3324/haematol.2022.282115.
  24. Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199–206. doi: 10.1200/JCO.2010.29.8018.
  25. Gillessen S, Plutschow A, Fuchs M, et al. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: Long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). Lancet Haematol. 2021;8(4):e278–e288. doi: 10.1016/S2352-3026(21)00029-6.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright (c) 2023 Clinical Oncohematology